Welcome to our dedicated page for Cyclacel Pharma news (Ticker: CYCC), a resource for investors and traders seeking the latest updates and insights on Cyclacel Pharma stock.
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is a clinical-stage biopharmaceutical company whose news flow centers on cancer drug development, capital markets activity and strategic transactions. The company publicly describes its focus as developing cancer medicines based on cell cycle, epigenetics, transcriptional regulation and mitosis biology, with its lead candidate plogosertib, a PLK1 inhibitor, being evaluated in patients with solid tumors and hematological malignancies.
News updates for CYCC often include clinical and preclinical developments related to plogosertib. Cyclacel has highlighted independent studies showing that biliary tract cancer and fibrolamellar hepatocellular carcinoma cells can be sensitive to PLK1 inhibition with plogosertib, as well as early Phase 1 data where oral plogosertib was reported to be well tolerated without dose-limiting toxicity in several dosing schedules. These items give investors and researchers insight into how external and internal data may shape the company’s oncology pipeline.
Cyclacel’s news also covers financial results and funding events, such as quarterly earnings updates, private placements of convertible preferred stock with accompanying warrants, and declarations of quarterly cash dividends on its 6% Convertible Exchangeable Preferred Stock. In addition, the company has issued releases on Nasdaq listing matters, including notices about minimum bid price compliance and announcements of reverse stock splits that affect the share structure while maintaining the CYCC ticker on The Nasdaq Capital Market.
Another recurring theme in Cyclacel news is strategic alternatives and corporate transactions. The company has discussed evaluating options to continue as a going concern and has announced an Exchange Agreement to acquire Fitters Sdn. Bhd., a Malaysia-based fire safety and protective equipment business, in a share and cash transaction subject to approvals. For investors tracking CYCC, following these news items helps monitor both the scientific progress of plogosertib and the company’s evolving capital structure and business direction.
Cyclacel Pharmaceuticals, Inc. will release its first quarter 2024 financial results on May 14, 2024. The company focuses on developing innovative cancer treatments and will host a conference call and webcast to discuss the results.
Cyclacel Pharmaceuticals, a biopharmaceutical company, closed an $8.0 million private placement under NASDAQ rules, offering shares of common stock, series A warrants, and short-term series B warrants. The gross proceeds were $8.0 million, with H.C. Wainwright & Co. as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes.
Cyclacel Pharmaceuticals, Inc. announced an $8.0 million private placement under Nasdaq rules, offering shares of common stock and warrants to purchase more shares at a fixed price. The placement is expected to close on May 2, 2024, with H.C. Wainwright & Co. acting as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.